宜明昂科-B(01541.HK) 公布,集团独立研发的IMM0306(一种靶向CD47xCD20的原创新药双特异性抗体)治疗视神经脊髓炎谱系疾病的Ib期临床试验成功完成首例患者给药,且并无不良事件报告。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-17 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.